FY2022 Earnings Forecast for Harrow Health, Inc. Issued By B. Riley (NASDAQ:HROW)

Harrow Health, Inc. (NASDAQ:HROWGet Rating) – Equities research analysts at B. Riley decreased their FY2022 earnings per share (EPS) estimates for Harrow Health in a note issued to investors on Tuesday, November 15th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.46) for the year, down from their previous forecast of ($0.25). B. Riley has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Harrow Health’s current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Harrow Health’s Q4 2022 earnings at ($0.14) EPS and FY2023 earnings at ($0.22) EPS.

Harrow Health Stock Performance

HROW stock opened at $10.47 on Friday. The company has a debt-to-equity ratio of 83.80, a quick ratio of 4.61 and a current ratio of 3.49. The stock has a market capitalization of $283.42 million, a price-to-earnings ratio of -12.61 and a beta of 0.41. Harrow Health has a 1 year low of $5.40 and a 1 year high of $13.29. The stock’s fifty day moving average is $10.97 and its two-hundred day moving average is $8.57.

Insider Buying and Selling at Harrow Health

In other Harrow Health news, Director Richard L. Md Lindstrom sold 40,000 shares of the firm’s stock in a transaction on Friday, September 30th. The stock was sold at an average price of $12.62, for a total value of $504,800.00. Following the sale, the director now directly owns 26,100 shares in the company, valued at $329,382. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Opaleye Management Inc. acquired 11,085 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The shares were acquired at an average cost of $9.77 per share, for a total transaction of $108,300.45. Following the completion of the purchase, the insider now directly owns 3,185,000 shares in the company, valued at $31,117,450. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard L. Md Lindstrom sold 40,000 shares of Harrow Health stock in a transaction dated Friday, September 30th. The shares were sold at an average price of $12.62, for a total transaction of $504,800.00. Following the sale, the director now owns 26,100 shares in the company, valued at $329,382. The disclosure for this sale can be found here. 14.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its holdings in Harrow Health by 530.7% during the third quarter. Tower Research Capital LLC TRC now owns 2,756 shares of the company’s stock worth $33,000 after acquiring an additional 2,319 shares during the period. Barclays PLC grew its holdings in Harrow Health by 44.3% during the third quarter. Barclays PLC now owns 3,560 shares of the company’s stock worth $43,000 after acquiring an additional 1,093 shares during the period. Captrust Financial Advisors acquired a new position in Harrow Health during the second quarter worth about $51,000. Truist Financial Corp acquired a new position in Harrow Health during the first quarter worth about $68,000. Finally, Envestnet Asset Management Inc. acquired a new position in Harrow Health during the first quarter worth about $70,000. 59.83% of the stock is owned by institutional investors and hedge funds.

Harrow Health Company Profile

(Get Rating)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Read More

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.